

ABSTRACT

Spinal cord injury (SCI) is a devastating disorder with no cure or effective treatment. Presently, the ideal therapy would improve the quality of life for SCI patients. Numerous studies have demonstrated the use of stem cells for treating various pathological states. Clinical studies have demonstrated that transplantation of autologous CD34+ stem cells ameliorate the symptoms of several disorders such as leukemia, cardiomyopathy, diabetes, and autoimmune diseases including multiple sclerosis. Here we report a safety and feasibility trial with 2 years follow up of 8 SCI patients (4 acute, 4 chronic) administered with autologous bone marrow stem cells (BMSCs) via multiple route delivery. The study demonstrated changes in magnetic resonance imaging, improvements in Asia, Barthel (quality of life), Frankel, Ashworth scoring and bladder function following BMSCs administration. These studies demonstrate that BMSCs administration via multiple routes is feasible, safe, meeting our primary end points and may improve the quality of life for patients living with SCI. Presently, we have administrated BMSCs into 46 paraplegic patients with greater than 6 months follow up. Our data demonstrates that administration of BMSCs via multiple routes is safe and feasible. Most importantly we had no tumor formations, no cases of infection or increased pain, and few instances of minor adverse events.

Magnetic Resonance Imaging demonstrates morphological changes in the spinal cord following administration of BMSCs



Neurological Evaluations

Demographics of SCI Patients

Administered with BMNCs

1.3

FACS analysis

FACS analysis demonstrates expression of CD34 +

stem cells in the bone marrow of spinal cord injury

patients

Case Study	Prior to	6 Months after	1 Year after	2 Years after
	Administration	Administration	Administration	Administration
	ASIA IMPAIRMENT GR	ADE/FRANKEL GRADI	/ASHWORTH SCORE	
Acute				
Case 1	A/B/0	C/C/2	C/C/3	C/C/1
Case 2	A/A/3	A/C/1	A/C/1	C/C/2**
Case 3	A/A/0	ND	A/C/1	A/C/1
Case 4	A/A/0	C/C/1	C/C/1	C/C/1
Chronic				
Case 5	B/C/1	B/C/0	C/D/1	C/D/1
Case 6	C/D/3.5	C/D/3	D/D/3.5	D/D/ND
Case 7	A/A/0	C/C/1	C/C/1	C/C/1+*
Case 8	C/C/2	C/C/2	C/D/1	C/D/0
ND- Not done	*1 year 3 months		**1 year 6 months	


SCI Patients were evaluated using the American Spinal Injury Association (ASIA) and Frankel scale. The modified Ashworth scoring system was used to measure changes in spasticity.

Geffner et al., 20

Administration of BMSCs following SCI Improves ASIA Motor and Sensory Scores


Case Study	Prior to	6 Months after	1 Year after	2 Years after		
	Administration	Administration	Administration	Administration		
ASIA Motor Score/Sensory Light Touch Score/Sensory Pin Prick Score						
Acute						
Case 1	50/64/64	54/72/72	54/83/80	56/90/90		
Case 2	50/49/49	52/50/50	52/54/54	52/54/57*		
Case 3	50/42/42	ND	51/58/58	51/60/64		
Case 4	50/76/76	52/78/78	56/80/82	58/80/84		
Chronic						
Case 5	52/88/88	54/88/88	64/100/101	68/100/101		
Case 6	62/66/66	62/80/80	78/94/94	85/94/94		
Case 7	50/70/70	54/70/70	54/70/73	61/72/73**		
Case 8	58/86/86	58/88/88	66/98/98	70/98/98		
ND- Not done		*1 year 3 months	*	*1 year 6 months		


ASIA motor and ASIA sensory (light touch and pin prick) scoring demonstrate improvements following administration of BMSCs into spinal cord injury patients



Administration of Adult Bone Marrow Stem Cells into Spinal Cord Injury Patients via Multiple Routes is Safe and Feasible

Rafael Gonzalez ‡, L. F. Geffner,* P. Santacruz,* M. Izurieta,* L. Flor,* B. Maldonado,†, A. H. Auad,* X. Montenegro,* and F. Silva‡ ‡DaVinci Biosciences, LLC, Costa Mesa, CA, USA; *Hospital Luis Vernaza, JBGYE, Guayaquil, Ecuador; †SOLCA, Guayaquil, Ecuador





SUMMARY

- 1. Administration of bone marrow stem cells via multiple routes is feasible and safe.
- 2. Two year follow up of administration of bone marrow stem cells demonstrates that it may improve the quality of life for acute and chronic spinal cord injury patients.
- 3. Presently we have administered 46 patients with bone marrow stem cells without any cases of infection, tumor formation, or increased pain.